The Situation:
An Ancillare customer was reporting excessive rogue spending by investigator sites marked by repeat reorder requests for product and frequent purchase of products without prior approval. Clinical trial product spending was excessive and the lack of product standardization lead to questions about the validity of the trial claims from the investigator sites. With no way of tracking actual site usage, there was no guarantee that trials were performed according to protocol specifications.
The Solution:
Our APTs deployed an approved version of the Ancillare Research and Development Management System creating approved product storefronts, buying limits, stocking programs, demand analysis and patient distribution scheduling, order tracking, and product administration analysis. The system effectively monitored all site usage patterns and automatically updated stocking programs based on additions to the patient database. The APT and ARDMS did not require additional involvement by the customer and managed the process through one source with full documentation to satisfy all protocol requirements.
The Result:
The APT and ARDMS allowed for full process accountability by monitoring site level activity and recording events throughout the progression of the protocol to ensure that all guidelines were followed exactly. As a result of the unique solution, the customer obtained double digit savings while gaining oversight over trial activities at no additional personnel cost. All rogue spend was eliminated and full protocol standardization was achieved by using our model.
